摘要
Angiogenesis plays an important role in the occurrence and development of tumors.Registered tyrosine kinase inhibitors targeting vascular endothelial growth factor reduce angiogenesis.Apatinib,a tyrosine kinase inhibitor,can specifically inhibit vascular endothelial growth factor receptor 2,showing encouraging anti-tumor effects in a variety of tumors including advanced hepatocellular carcinoma(HCC).This article intends to review the clinical research and application prospects of apatinib in the field of HCC.